Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY-NC-ND 4.0BMC Pediatrics

Marked reduction of homogentisic acid with nitisinone in a child with alkaptonuria: a case report

  1. 1Pediatric Department, Ekbatan Hospital, Jahad Square, Hamadan University of Medical Sciences, Hamadan, Iran
  2. 2Clinical Pharmacy Department, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran

Abstract

Background: Alkaptonuria (AKU) is a rare autosomal recessive disorder caused by mutations in the homogentisate 1,2-dioxygenase (HGD) gene, resulting in impaired degradation of tyrosine and phenylalanine and subsequent accumulation of homogentisic acid (HGA). While dark urine may be the only clinical sign in childhood, progressive HGA deposition leads to severe manifestations in adulthood, including arthritis and cardiovascular complications.

Case presentation: We report the case of a 10-year-old boy in whom alkaptonuria was diagnosed early and successfully managed with Nitisinone, an inhibitor of 4-hydroxyphenylpyruvate dioxygenase that reduces HGA production.

Conclusion: Nitisinone represents a cornerstone of AKU management, though vigilant monitoring for hypertyrosinemia remains essential, especially in children.

Related

  1. Marked reduction in serum uric acid levels after empagliflozin initiation in a patient with heart failure
    Naoyuki Otani, Takushi Sugiyama, Yasuhiro Maejima
    BMJ Case ReportsPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
  2. Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study
    Yoichi Otomi, Takayoshi Shinya, Hideki Otsuka +11
    Japanese Journal of RadiologyPeer-reviewedCC BY 4.0Full textPhysiologyPMC
  3. Case Report: Marked intrafamilial variability and recurrent fever-associated alopecia in SREBF1-associated hereditary mucoepithelial dysplasia
    Mingyuan Xu, Lei Wang, Yonglong Xu +1
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Acute Pancreatitis Presenting With ST‐Segment Elevation and Marked Troponin Elevation: A Diagnostic Dilemma in a Resource‐Limited Setting—A Case Report
    Selamawit Kassahun Aweke, Natnael Mathewos Assale, Anteneh Girma Mengistu +4
    Clinical case reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Marked Hyperbilirubinemia in a Patient with Intrahepatic Cholestasis of Pregnancy and a UGT1A1 Polymorphism: A Case Report
    Natsuki Ishizaki, Manabu Hayashi, Tatsuro Sugaya +10
    Internal MedicinePeer-reviewedCC BY-NC-NDFull text1 citedObstetrics, gynaecology & paediatricsJ-STAGE
BibTeX
@article{momtaz2026marked,
  title = {{Marked reduction of homogentisic acid with nitisinone in a child with alkaptonuria: a case report}},
  author = {Hossein Emad Momtaz and Maryam Darabi and Nasibeh Ghalandari},
  journal = {BMC Pediatrics},
  year = {2026},
  month = aug,
  doi = {10.1186/s12887-026-07436-8},
  url = {https://doi.org/10.1186/s12887-026-07436-8},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Marked reduction of homogentisic acid with nitisinone in a child with alkaptonuria: a case report
AU  - Hossein Emad Momtaz
AU  - Maryam Darabi
AU  - Nasibeh Ghalandari
PY  - 2026
DA  - 2026/08/17
JO  - BMC Pediatrics
DO  - 10.1186/s12887-026-07436-8
UR  - https://doi.org/10.1186/s12887-026-07436-8
AB  - Background: Alkaptonuria (AKU) is a rare autosomal recessive disorder caused by mutations in the homogentisate 1,2-dioxygenase (HGD) gene, resulting in impaired degradation of tyrosine and phenylalanine and subsequent accumulation of homogentisic acid (HGA). While dark urine may be the only clinical sign in childhood, progressive HGA deposition leads to severe manifestations in adulthood, including arthritis and cardiovascular complications.  Case presentation: We report the case of a 10-year-old boy in whom alkaptonuria was diagnosed early and successfully managed with Nitisinone, an inhibitor of 4-hydroxyphenylpyruvate dioxygenase that reduces HGA production.  Conclusion: Nitisinone represents a cornerstone of AKU management, though vigilant monitoring for hypertyrosinemia remains essential, especially in children.
SN  - 1471-2431
ER  -